University College London Featured PhD Programmes
University of Glasgow Featured PhD Programmes
Sheffield Hallam University Featured PhD Programmes
Heriot-Watt University Featured PhD Programmes
Loughborough University Featured PhD Programmes

Targeting hematological malignancies using fragment-based drug design

  • Full or part time
    Dr V Veverka
  • Application Deadline
    Sunday, February 23, 2020
  • Competition Funded PhD Project (Students Worldwide)
    Competition Funded PhD Project (Students Worldwide)

Project Description

The project will be focused on the knowledge-based design of active compounds targeting several proteins or protein-protein interactions, which are implicated in the development of hematological malignancies (acute lymphoblastic leukemia and mixed-lineage leukemia). The compounds will be developed using the fragment-based approach. The work on this project provides the opportunity to acquire expertise in protein biochemistry, biophysics and structural biology (NMR spectroscopy and X-ray crystallography), as well as to get an insight into the rational drug design process through close collaboration with the medicinal and computational chemists.

How to apply

To apply for a PhD study at IOCB Prague, you must hold a Master’s degree (MSc) or the equivalent of the MSc in similar field (four or five year undergraduate degree). The application can be submitted before obtaining the Master’s degree, however, the applicant should obtain the degree within five months after the application deadline.

For more information visit our website “Call for PhD applications 2020”:

If you decided to apply, please do so online via our application form:

Funding Notes

Regular monthly income of students at IOCB Prague varies depending on the faculty scholarship and supervisor's financial options.


Hnizda, A., et al.,Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. Leukemia 2018, 32 (6), 1393.

Čermáková, K., et al., Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia. Cancer Research, 2014. 74 (18): 5139.

Related Subjects

FindAPhD. Copyright 2005-2020
All rights reserved.